Welcome to our dedicated page for Emmaus Life Scie SEC filings (Ticker: EMMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Emmaus Life Sciences filings document formal disclosures for a commercial-stage biopharmaceutical company focused on Endari® for sickle cell disease. Recent Form 8-K reports cover operating results and financial condition, material agreements involving Endari commercialization and supply, and capital-structure actions such as convertible note exchanges and common stock issuance.
The filing record also includes governance disclosures on director resignations, board appointments, audit committee membership, and compensatory arrangements. Emmaus filings identify its public-company context, securities-registration status, exhibit filings, liquidity, derivative liabilities, debt restructuring, and other matters tied to its regulated biopharmaceutical business.
Emmaus Life Sciences reported first-quarter 2026 results showing lower revenue but reduced operating expenses. Net revenues for the three months ended March 31, 2026 were $2.0 million, down 18% from $2.4 million a year earlier, mainly from a 33% decline in U.S. sales amid generic L-glutamine competition, partly offset by a 446% increase in sales in the MENA region.
Total operating expenses fell to $2.6 million from $3.2 million, improving loss from operations to $0.8 million compared with $1.0 million. However, higher interest and derivative-related costs drove other expense up to $2.5 million, increasing net loss to $3.3 million, or $0.05 per share, versus $2.3 million, or $0.04 per share. Cash and cash equivalents were $1.1 million at March 31, 2026, with total liabilities of $86.6 million and a stockholders’ deficit of $67.9 million.
Emmaus Life Sciences reported a challenging quarter for the three months ended March 31, 2026. Revenue was $1.98 million, down from $2.41 million a year earlier, while net loss widened to $3.34 million from $2.33 million. Basic and diluted loss per share was $0.05 on 70.2 million weighted-average shares.
Total assets were $18.7 million against total liabilities of $86.6 million, resulting in a stockholders’ deficit of $67.9 million and cash of only $1.07 million. Management discloses a working capital deficit of $64.5 million and states there is substantial doubt about the company’s ability to continue as a going concern without restructuring debt or raising additional capital.
U.S. Endari® revenue declined sharply, partially offset by growth in international sales. The company continues to rely on high-interest debt, convertible notes and related‑party loans while managing a sizeable convertible bond investment in Telcon. Subsequent to quarter end, its U.S. Endari® license and supply arrangements with NeoImmuneTech became effective, shifting future U.S. revenue toward supply sales and royalties.
Emmaus Life Sciences, Inc. director Du Henry Huy filed an initial Form 3 reporting his status as a director of the company. The filing shows no reportable transactions, no reported common stock holdings, and no derivative securities positions, with all transaction and holding counts recorded as zero.
Emmaus Life Sciences, Inc. appointed Henry H. Du to its Board of Directors by written consent on April 16, 2026, filling the vacancy created by the recent resignation of Jon Kuwahara. He is also expected to replace Mr. Kuwahara as the sole member of the Board’s Audit Committee.
Mr. Du, age 48, is Vice President – Finance Accounting and interim Chief Financial Officer of Alpha Cognition, Inc., a biopharmaceutical company, and is a Certified Public Accountant with a Bachelor of Arts degree from Claremont McKenna College. Emmaus states there are no family relationships or related-party transactions requiring disclosure, and that he will be compensated like its other directors.
Emmaus Life Sciences, Inc. reported that director Jon Kuwahara resigned from its board. The resignation was dated April 13, 2026 and becomes effective April 15, 2026. The company also identified a cover page interactive data file as Exhibit 104 embedded within the inline XBRL document.
Emmaus Life Sciences reported full-year 2025 results showing sharply lower sales but improved operating performance. Net revenue was $12.5 million, down 25% from $16.7 million in 2024, mainly due to U.S. competition from generic L-glutamine, partly offset by higher sales in the MENA region.
Total operating expenses fell 34% to $11.4 million from $17.3 million, turning a $0.2 million income from operations versus a $1.9 million operating loss a year earlier. However, other expense rose to $7.5 million from $4.5 million, driven by higher loss on debt extinguishment and interest expense and lower gains on restructured debt.
Emmaus recorded a 2025 net loss of $7.2 million (or $0.12 per share) compared with a $6.5 million net loss (or $0.10 per share) in 2024. At December 31, 2025, cash and equivalents were $2.1 million versus $1.4 million a year earlier, while total liabilities were $85.0 million and stockholders’ deficit was $63.6 million. Management is shifting U.S. strategy through a license and exclusive distribution arrangement with NeoImmuneTech and emphasizes international growth for Endari.
Emmaus Life Sciences, Inc. reports continued operating losses and severe liquidity pressure, with a comprehensive loss of $7.2 million in 2025 and a working capital deficit of $61.3 million. The auditor included a going concern paragraph as the company depends on restructuring or refinancing significant debt and raising new capital.
Emmaus’ business centers on its only product, Endari, for sickle cell disease, now facing U.S. generic competition after orphan exclusivity expired in July 2024. A new License and Exclusive Distribution Agreement with NeoImmuneTech (NIT) would shift U.S. commercialization to NIT, but the Effective Date depends on regulatory and other conditions and may never occur. Outside the U.S., Emmaus is expanding Endari in the MENA region, but relies on single‑source suppliers and packagers and must navigate longer reimbursement cycles and geopolitical risks.
Emmaus Life Sciences has entered into an Exclusive Supply Agreement with NeoImmuneTech (NIT), building on a prior license that grants NIT exclusive rights to market and distribute Endari for sickle cell disease in the U.S., its territories and possessions, and Canada.
The new agreement provides that, once the License Agreement’s “Effective Date” occurs, Emmaus will supply Endari and any generic equivalents exclusively to NIT, and NIT will, with limited exceptions, purchase all of its product requirements from Emmaus at a price equal to Emmaus’ production cost plus a specified double‑digit percentage margin.
The Effective Date depends on NIT obtaining required regulatory approvals and other conditions, and may never be reached. Either party may terminate the License Agreement if the Effective Date has not occurred by October 1, 2026, unless the delay results from wrongful acts by Emmaus.
Emmaus Life Sciences entered into a License and Exclusive Distribution Agreement with NeoImmuneTech (NIT) giving NIT exclusive rights to market, sell, and distribute Endari and its generic equivalents for sickle cell disease in the U.S., its territories, and Canada. In return, Emmaus receives an upfront payment and ongoing royalties on NIT’s product sales.
Once the agreement’s “Effective Date” occurs, Emmaus will also become NIT’s exclusive supplier of Endari for this use and region at a price based on Emmaus’ production cost plus an agreed margin. The Effective Date depends on NIT obtaining required regulatory approvals and other conditions, and the agreement can be terminated if these are not met by October 1, 2026. If NIT does not achieve specified minimum annual sales after the Effective Date, its rights become nonexclusive, while Emmaus keeps all Endari rights outside this disease area and territory.
Emmaus Life Sciences, Inc. entered into an exchange agreement with a single noteholder on December 17, 2025. The company agreed to issue 6,332,692 shares of common stock valued at approximately $0.38 per share and a new convertible promissory note with a principal amount of $600,000. In return, the holder surrendered for cancellation an outstanding convertible promissory note with a principal amount of $3,000,000 that was already due and payable.
The cancelled note carried 10% annual interest and was convertible at $0.13 per share. The new note also bears 10% annual interest and is initially convertible at $0.01 per share, subject to quarterly reset to the average VWAP if that is lower, and to adjustment for stock splits and similar events. The principal on the new note is due on demand, and no additional cash consideration was exchanged. The securities will be issued without registration in reliance on the Section 3(a)(9) exemption.